Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles

被引:161
作者
Sasaki, Hirofumi
Haraguchi, Yoshikazu
Itotani, Motohiro
Kuroda, Hideaki
Hashizume, Hiroyuki
Tomishige, Tatsuo
Kawasaki, Masanori
Matsumoto, Makoto
Komatsu, Makoto
Tsubouchi, Hidetsugu
机构
[1] Otsuka Pharmaceut Co Ltd, Med Chem Res Inst, Kawaguchi, Tokushima 7710192, Japan
[2] Otsuka Pharmaceut Co Ltd, Microbiol Res Inst, Tokushima 7710192, Japan
关键词
D O I
10.1021/jm060957y
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
In an effort to develop potent new antituberculosis agents that would be effective against both drug-susceptible and drug-resistant strains of Mycobacterium tuberculosis, we prepared a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles substituted at the 2-position with various phenoxymethyl groups and a methyl group and investigated the in vitro and in vivo activity of these compounds. Several of these derivatives showed potent in vitro and in vivo activity, and compound 19 (OPC-67683) in particular displayed excellent in vitro activity against both drug-susceptible and drug-resistant strains of M. tuberculosis H(37)Rv (MIC = 0.006 mu g/mL) and dose-dependent and significant in vivo efficacy at lower oral doses than rifampicin in mouse models infected with M. tuberculosis Kurono. The synthesis and structure-activity relationships of these new compounds are presented.
引用
收藏
页码:7854 / 7860
页数:7
相关论文
共 28 条
[1]   INVITRO AND INVIVO ACTIVITIES OF THE NITROIMIDAZOLE CGI-17341 AGAINST MYCOBACTERIUM-TUBERCULOSIS [J].
ASHTEKAR, DR ;
COSTAPERIRA, R ;
NAGRAJAN, K ;
VISHVANATHAN, N ;
BHATT, AD ;
RITTEL, W .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (02) :183-186
[2]   TREATMENT OF TUBERCULOSIS AND TUBERCULOSIS INFECTION IN ADULTS AND CHILDREN [J].
BASS, JB ;
FARER, LS ;
HOPEWELL, PC ;
OBRIEN, R ;
JACOBS, RF ;
RUBEN, F ;
SNIDER, DE ;
THORNTON, G .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1994, 149 (05) :1359-1374
[3]   Comparison of the in vitro activities of rifapentine and rifampicin against Mycobacterium tuberculosis complex [J].
Bemer-Melchior, P ;
Bryskier, A ;
Drugeon, HB .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 46 (04) :571-575
[4]   Activity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium avium [J].
Bermudez, LE ;
Inderlied, CB ;
Kolonoski, P ;
Petrofsky, M ;
Aralar, P ;
Wu, M ;
Young, LS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (01) :217-222
[5]   Metronidazole therapy in mice infected with tuberculosis [J].
Brooks, JV ;
Furney, SK ;
Orme, IM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (05) :1285-1288
[6]   Treatment of HIV-related tuberculosis in the era of effective antiretroviral therapy [J].
Burman, WJ ;
Jones, BE .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2001, 164 (01) :7-12
[7]   High-dose isoniazid therapy for isoniazid-resistant murine Mycobacterium tuberculosis infection [J].
Cynamon, MH ;
Zhang, Y ;
Harpster, T ;
Cheng, S ;
DeStefano, MS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (12) :2922-2924
[8]   Progress in TB drug development and what is still needed [J].
Duncan, K .
TUBERCULOSIS, 2003, 83 (1-3) :201-207
[9]   Global burden of tuberculosis - Estimated incidence, prevalence, and mortality by country [J].
Dye, C ;
Scheele, S ;
Dolin, P ;
Pathania, V ;
Raviglione, RC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (07) :677-686
[10]   THERAPY OF MYCOBACTERIUM-AVIUM COMPLEX INFECTIONS IN BEIGE MICE WITH STREPTOMYCIN ENCAPSULATED IN STERICALLY STABILIZED LIPOSOMES [J].
GANGADHARAM, PRJ ;
ASHTEKAR, DR ;
FLASHER, DL ;
DUZGUNES, N .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (03) :725-730